BioSpace News Archive

Their results could lead the way to a new therapeutic target to treat pancreatitis, a known risk factor for pancreatic cancer.

The Series F preferred stock is convertible into shares of the company’s common stock at a conversion price of $4.50 per share.

SCRS’ GIP Program provides a unique opportunity for sponsors, CROs and vendors to engage with SCRS and its members in an impactful manner.

The second appellate brief filed to seek reversal of patent board decision on CRISPR/CAS9 gene editing, expected to result in 2018 oral hearing.

To apply for the award, OCT provided information about its business and shared some notable achievements over the last 12 months.

According to the data analysis of financial department at Alfa Chemistry, the sales of Steroidal Compounds is expected to grow at annual growth rate of 5% during 2016-2017.

- Specialised Therapeutics Asia to make NERLYNX® (neratinib) available in Australia, New Zealand and South-East Asia for women with early-stage, HER2+ breast cancer following exclusive license agreement - Five-year follow up data shows NERLYNX reduces risk of invasive disease recurrence by 27% in women with early-stage, HER2+ breast cancer - Special Access Program to open in Australia Q1 2018 followed by other countries in the territory

The term sheet is preliminary and non-binding at this stage and the license, upfront payment, possible milestone payments, and royalties contemplated by it will only become operative if definitive documents are executed.

As of September 30, 2017, cash was $3.1 million, compared to $0.7 million as of December 31, 2016.

The recently launched detectors are lightweight1 and IPX7 rated2 devices that feature limited on-board image storage capability when operated in Standalone Mode3 and an ergonomic detector design.